Opioid-induced constipation (OIC) is a common adverse effect experienced by many patients on opioid therapy for chronic pain. OTC medications include stimulant laxatives, stool softeners, and enemas.
The global Opioid Induced Constipation (OIC) Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the Opioid Induced Constipation (OIC) Drug production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Opioid Induced Constipation (OIC) Drug by regions (countries) and by Application.
The global Opioid Induced Constipation (OIC) Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Opioid Induced Constipation (OIC) Drug market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Opioid Induced Constipation (OIC) Drug markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Opioid Induced Constipation (OIC) Drug market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Opioid Induced Constipation (OIC) Drug market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Opioid Induced Constipation (OIC) Drug market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Opioid Induced Constipation (OIC) Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each application segment for the same period.
This report includes the following manufacturers:
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Market Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Market Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Research Methodology
To compile the detailed study of the global Opioid Induced Constipation (OIC) Drug market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Opioid Induced Constipation (OIC) Drug market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Opioid Induced Constipation (OIC) Drug market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
The global Opioid Induced Constipation (OIC) Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the Opioid Induced Constipation (OIC) Drug production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of Opioid Induced Constipation (OIC) Drug by regions (countries) and by Application.
The global Opioid Induced Constipation (OIC) Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Opioid Induced Constipation (OIC) Drug market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise Opioid Induced Constipation (OIC) Drug markets such as North America, Europe, China and Japan, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Opioid Induced Constipation (OIC) Drug market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
Manufacturers
The report includes comprehensive company profiling of leading and emerging companies competing in the global Opioid Induced Constipation (OIC) Drug market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global Opioid Induced Constipation (OIC) Drug market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global Opioid Induced Constipation (OIC) Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global Opioid Induced Constipation (OIC) Drug market by each application segment for the same period.
This report includes the following manufacturers:
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Market Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Market Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Research Methodology
To compile the detailed study of the global Opioid Induced Constipation (OIC) Drug market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Opioid Induced Constipation (OIC) Drug market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Opioid Induced Constipation (OIC) Drug market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Type
1.2.2 Lubiprostone
1.2.3 Methyl Naltrexone Bromide
1.2.4 Naldemedine
1.2.5 Alvimopan
1.2.6 Other
1.3 Market Segment by Application
1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Opioid Induced Constipation (OIC) Drug Market Size (2016-2027)
2.1.1 Global Opioid Induced Constipation (OIC) Drug Revenue (2016-2027)
2.1.2 Global Opioid Induced Constipation (OIC) Drug Sales (2016-2027)
2.2 Global Opioid Induced Constipation (OIC) Drug Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Opioid Induced Constipation (OIC) Drug Sales by Regions (2016-2021)
2.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Regions (2016-2021)
2.3 Global Opioid Induced Constipation (OIC) Drug Market Size Forecast by Region
2.3.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Region (2022-2027)
2.3.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Region (2022-2027)
2.4 Global Top Opioid Induced Constipation (OIC) Drug Regions (Countries) Ranking by Market Size
2.5 Opioid Induced Constipation (OIC) Drug Industry Trends
2.5.1 Opioid Induced Constipation (OIC) Drug Market Trends
2.5.2 Opioid Induced Constipation (OIC) Drug Market Drivers
2.5.3 Opioid Induced Constipation (OIC) Drug Market Challenges
2.5.4 Opioid Induced Constipation (OIC) Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Opioid Induced Constipation (OIC) Drug Manufacturers by Sales (2016-2021)
3.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Manufacturers (2016-2021)
3.1.2 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Opioid Induced Constipation (OIC) Drug Sales in 2020
3.2 Global Top Manufacturers Opioid Induced Constipation (OIC) Drug by Revenue
3.2.1 Global Opioid Induced Constipation (OIC) Drug Revenue by Manufacturers (2016-2021)
3.2.2 Top Opioid Induced Constipation (OIC) Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Opioid Induced Constipation (OIC) Drug Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Opioid Induced Constipation (OIC) Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation (OIC) Drug as of 2020)
3.4 Global Opioid Induced Constipation (OIC) Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Opioid Induced Constipation (OIC) Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market
3.7 Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Opioid Induced Constipation (OIC) Drug Market Size by Type
4.1 Global Opioid Induced Constipation (OIC) Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Type (2016-2021)
4.1.3 Opioid Induced Constipation (OIC) Drug Price by Type (2016-2021)
4.2 Global Opioid Induced Constipation (OIC) Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Type (2022-2027)
4.2.3 Opioid Induced Constipation (OIC) Drug Price Forecast by Type (2022-2027)
5 Global Opioid Induced Constipation (OIC) Drug Market Size by Application
5.1 Global Opioid Induced Constipation (OIC) Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Application (2016-2021)
5.1.3 Opioid Induced Constipation (OIC) Drug Price by Application (2016-2021)
5.2 Global Opioid Induced Constipation (OIC) Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Application (2022-2027)
5.2.3 Opioid Induced Constipation (OIC) Drug Price Forecast by Application (2022-2027)
6 North America
6.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
6.1.1 North America Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
6.1.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
6.2 North America Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
6.2.1 North America Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
6.2.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
6.3 North America Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
6.3.1 North America Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
6.3.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
6.4 North America Opioid Induced Constipation (OIC) Drug Market Size by Country
6.4.1 North America Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
6.4.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
7.1.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
7.1.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
7.2 Europe Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
7.2.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
7.2.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
7.3 Europe Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
7.3.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
7.3.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
7.4 Europe Opioid Induced Constipation (OIC) Drug Market Size by Country
7.4.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
7.4.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
8.1.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
8.1.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
8.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
8.2.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
8.2.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
8.3 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
8.3.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
8.3.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
8.4 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Regions
8.4.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Regions
8.4.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
9.1.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
9.1.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
9.2 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
9.2.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
9.2.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
9.3 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
9.3.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
9.3.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
9.4 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Country
9.4.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
9.4.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
10.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
10.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
10.2.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
10.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
10.3.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
10.4 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country
10.4.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
10.4.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Ironwood Pharmaceuticals
11.1.1 Ironwood Pharmaceuticals Corporation Information
11.1.2 Ironwood Pharmaceuticals Overview
11.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.1.5 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.1.6 Ironwood Pharmaceuticals Recent Developments
11.2 Daiichi Sankyo Co
11.2.1 Daiichi Sankyo Co Corporation Information
11.2.2 Daiichi Sankyo Co Overview
11.2.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Products and Services
11.2.5 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.2.6 Daiichi Sankyo Co Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Products and Services
11.3.5 Pfizer Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.3.6 Pfizer Recent Developments
11.4 Progenics Pharmaceuticals
11.4.1 Progenics Pharmaceuticals Corporation Information
11.4.2 Progenics Pharmaceuticals Overview
11.4.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.4.5 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.4.6 Progenics Pharmaceuticals Recent Developments
11.5 Shionogi &
11.5.1 Shionogi & Corporation Information
11.5.2 Shionogi & Overview
11.5.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Products and Services
11.5.5 Shionogi & Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.5.6 Shionogi & Recent Developments
11.6 Allergan
11.6.1 Allergan Corporation Information
11.6.2 Allergan Overview
11.6.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 Allergan Opioid Induced Constipation (OIC) Drug Products and Services
11.6.5 Allergan Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.6.6 Allergan Recent Developments
11.7 Nektar Therapeutics
11.7.1 Nektar Therapeutics Corporation Information
11.7.2 Nektar Therapeutics Overview
11.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Products and Services
11.7.5 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.7.6 Nektar Therapeutics Recent Developments
11.8 Purdue Pharma
11.8.1 Purdue Pharma Corporation Information
11.8.2 Purdue Pharma Overview
11.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Products and Services
11.8.5 Purdue Pharma Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.8.6 Purdue Pharma Recent Developments
11.9 S.L.A. Pharma
11.9.1 S.L.A. Pharma Corporation Information
11.9.2 S.L.A. Pharma Overview
11.9.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Products and Services
11.9.5 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.9.6 S.L.A. Pharma Recent Developments
11.10 Mundipharma International Limited
11.10.1 Mundipharma International Limited Corporation Information
11.10.2 Mundipharma International Limited Overview
11.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Products and Services
11.10.5 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.10.6 Mundipharma International Limited Recent Developments
11.11 Ono Pharmaceutical
11.11.1 Ono Pharmaceutical Corporation Information
11.11.2 Ono Pharmaceutical Overview
11.11.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.11.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Products and Services
11.11.5 Ono Pharmaceutical Recent Developments
11.12 Takeda Pharmaceutical Company Limited
11.12.1 Takeda Pharmaceutical Company Limited Corporation Information
11.12.2 Takeda Pharmaceutical Company Limited Overview
11.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Products and Services
11.12.5 Takeda Pharmaceutical Company Limited Recent Developments
11.13 Theravance Biopharma
11.13.1 Theravance Biopharma Corporation Information
11.13.2 Theravance Biopharma Overview
11.13.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.13.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Products and Services
11.13.5 Theravance Biopharma Recent Developments
11.14 Bausch Health
11.14.1 Bausch Health Corporation Information
11.14.2 Bausch Health Overview
11.14.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.14.4 Bausch Health Opioid Induced Constipation (OIC) Drug Products and Services
11.14.5 Bausch Health Recent Developments
11.15 Cosmo Pharmaceuticals SA
11.15.1 Cosmo Pharmaceuticals SA Corporation Information
11.15.2 Cosmo Pharmaceuticals SA Overview
11.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Products and Services
11.15.5 Cosmo Pharmaceuticals SA Recent Developments
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Corporation Information
11.16.2 Daewoong Pharmaceutical Overview
11.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Products and Services
11.16.5 Daewoong Pharmaceutical Recent Developments
11.17 C.B. Fleet Company
11.17.1 C.B. Fleet Company Corporation Information
11.17.2 C.B. Fleet Company Overview
11.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Products and Services
11.17.5 C.B. Fleet Company Recent Developments
11.18 Sucampo Pharmaceuticals
11.18.1 Sucampo Pharmaceuticals Corporation Information
11.18.2 Sucampo Pharmaceuticals Overview
11.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.18.5 Sucampo Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Opioid Induced Constipation (OIC) Drug Value Chain Analysis
12.2 Opioid Induced Constipation (OIC) Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid Induced Constipation (OIC) Drug Production Mode & Process
12.4 Opioid Induced Constipation (OIC) Drug Sales and Marketing
12.4.1 Opioid Induced Constipation (OIC) Drug Sales Channels
12.4.2 Opioid Induced Constipation (OIC) Drug Distributors
12.5 Opioid Induced Constipation (OIC) Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Type
1.2.2 Lubiprostone
1.2.3 Methyl Naltrexone Bromide
1.2.4 Naldemedine
1.2.5 Alvimopan
1.2.6 Other
1.3 Market Segment by Application
1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Opioid Induced Constipation (OIC) Drug Market Size (2016-2027)
2.1.1 Global Opioid Induced Constipation (OIC) Drug Revenue (2016-2027)
2.1.2 Global Opioid Induced Constipation (OIC) Drug Sales (2016-2027)
2.2 Global Opioid Induced Constipation (OIC) Drug Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global Opioid Induced Constipation (OIC) Drug Sales by Regions (2016-2021)
2.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue by Regions (2016-2021)
2.3 Global Opioid Induced Constipation (OIC) Drug Market Size Forecast by Region
2.3.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Region (2022-2027)
2.3.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Region (2022-2027)
2.4 Global Top Opioid Induced Constipation (OIC) Drug Regions (Countries) Ranking by Market Size
2.5 Opioid Induced Constipation (OIC) Drug Industry Trends
2.5.1 Opioid Induced Constipation (OIC) Drug Market Trends
2.5.2 Opioid Induced Constipation (OIC) Drug Market Drivers
2.5.3 Opioid Induced Constipation (OIC) Drug Market Challenges
2.5.4 Opioid Induced Constipation (OIC) Drug Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Opioid Induced Constipation (OIC) Drug Manufacturers by Sales (2016-2021)
3.1.1 Global Opioid Induced Constipation (OIC) Drug Sales by Manufacturers (2016-2021)
3.1.2 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by Opioid Induced Constipation (OIC) Drug Sales in 2020
3.2 Global Top Manufacturers Opioid Induced Constipation (OIC) Drug by Revenue
3.2.1 Global Opioid Induced Constipation (OIC) Drug Revenue by Manufacturers (2016-2021)
3.2.2 Top Opioid Induced Constipation (OIC) Drug Manufacturers Covered: Ranking by Revenue
3.2.3 Global Opioid Induced Constipation (OIC) Drug Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Opioid Induced Constipation (OIC) Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation (OIC) Drug as of 2020)
3.4 Global Opioid Induced Constipation (OIC) Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Opioid Induced Constipation (OIC) Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market
3.7 Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Opioid Induced Constipation (OIC) Drug Market Size by Type
4.1 Global Opioid Induced Constipation (OIC) Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Type (2016-2021)
4.1.3 Opioid Induced Constipation (OIC) Drug Price by Type (2016-2021)
4.2 Global Opioid Induced Constipation (OIC) Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Type (2022-2027)
4.2.3 Opioid Induced Constipation (OIC) Drug Price Forecast by Type (2022-2027)
5 Global Opioid Induced Constipation (OIC) Drug Market Size by Application
5.1 Global Opioid Induced Constipation (OIC) Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Opioid Induced Constipation (OIC) Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Application (2016-2021)
5.1.3 Opioid Induced Constipation (OIC) Drug Price by Application (2016-2021)
5.2 Global Opioid Induced Constipation (OIC) Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Opioid Induced Constipation (OIC) Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Forecast by Application (2022-2027)
5.2.3 Opioid Induced Constipation (OIC) Drug Price Forecast by Application (2022-2027)
6 North America
6.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
6.1.1 North America Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
6.1.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
6.2 North America Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
6.2.1 North America Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
6.2.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
6.3 North America Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
6.3.1 North America Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
6.3.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
6.4 North America Opioid Induced Constipation (OIC) Drug Market Size by Country
6.4.1 North America Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
6.4.2 North America Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
7.1.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
7.1.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
7.2 Europe Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
7.2.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
7.2.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
7.3 Europe Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
7.3.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
7.3.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
7.4 Europe Opioid Induced Constipation (OIC) Drug Market Size by Country
7.4.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
7.4.2 Europe Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
8.1.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
8.1.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
8.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
8.2.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
8.2.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
8.3 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
8.3.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
8.3.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
8.4 Asia Pacific Opioid Induced Constipation (OIC) Drug Market Size by Regions
8.4.1 Asia Pacific Opioid Induced Constipation (OIC) Drug Sales by Regions
8.4.2 Asia Pacific Opioid Induced Constipation (OIC) Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
9.1.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
9.1.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
9.2 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
9.2.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
9.2.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
9.3 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
9.3.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
9.3.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
9.4 Latin America Opioid Induced Constipation (OIC) Drug Market Size by Country
9.4.1 Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
9.4.2 Latin America Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Company
10.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Company (2016-2027)
10.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Company (2016-2027)
10.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Type (2016-2027)
10.2.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Type (2016-2027)
10.2.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Type (2016-2027)
10.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Application (2016-2027)
10.3.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Application (2016-2027)
10.3.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Application (2016-2027)
10.4 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country
10.4.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2016-2027)
10.4.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 U.A.E
11 Company Profiles
11.1 Ironwood Pharmaceuticals
11.1.1 Ironwood Pharmaceuticals Corporation Information
11.1.2 Ironwood Pharmaceuticals Overview
11.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.1.5 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.1.6 Ironwood Pharmaceuticals Recent Developments
11.2 Daiichi Sankyo Co
11.2.1 Daiichi Sankyo Co Corporation Information
11.2.2 Daiichi Sankyo Co Overview
11.2.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Products and Services
11.2.5 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.2.6 Daiichi Sankyo Co Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Products and Services
11.3.5 Pfizer Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.3.6 Pfizer Recent Developments
11.4 Progenics Pharmaceuticals
11.4.1 Progenics Pharmaceuticals Corporation Information
11.4.2 Progenics Pharmaceuticals Overview
11.4.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.4.5 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.4.6 Progenics Pharmaceuticals Recent Developments
11.5 Shionogi &
11.5.1 Shionogi & Corporation Information
11.5.2 Shionogi & Overview
11.5.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Products and Services
11.5.5 Shionogi & Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.5.6 Shionogi & Recent Developments
11.6 Allergan
11.6.1 Allergan Corporation Information
11.6.2 Allergan Overview
11.6.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.6.4 Allergan Opioid Induced Constipation (OIC) Drug Products and Services
11.6.5 Allergan Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.6.6 Allergan Recent Developments
11.7 Nektar Therapeutics
11.7.1 Nektar Therapeutics Corporation Information
11.7.2 Nektar Therapeutics Overview
11.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.7.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Products and Services
11.7.5 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.7.6 Nektar Therapeutics Recent Developments
11.8 Purdue Pharma
11.8.1 Purdue Pharma Corporation Information
11.8.2 Purdue Pharma Overview
11.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Products and Services
11.8.5 Purdue Pharma Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.8.6 Purdue Pharma Recent Developments
11.9 S.L.A. Pharma
11.9.1 S.L.A. Pharma Corporation Information
11.9.2 S.L.A. Pharma Overview
11.9.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Products and Services
11.9.5 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.9.6 S.L.A. Pharma Recent Developments
11.10 Mundipharma International Limited
11.10.1 Mundipharma International Limited Corporation Information
11.10.2 Mundipharma International Limited Overview
11.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Products and Services
11.10.5 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug SWOT Analysis
11.10.6 Mundipharma International Limited Recent Developments
11.11 Ono Pharmaceutical
11.11.1 Ono Pharmaceutical Corporation Information
11.11.2 Ono Pharmaceutical Overview
11.11.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.11.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Products and Services
11.11.5 Ono Pharmaceutical Recent Developments
11.12 Takeda Pharmaceutical Company Limited
11.12.1 Takeda Pharmaceutical Company Limited Corporation Information
11.12.2 Takeda Pharmaceutical Company Limited Overview
11.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Products and Services
11.12.5 Takeda Pharmaceutical Company Limited Recent Developments
11.13 Theravance Biopharma
11.13.1 Theravance Biopharma Corporation Information
11.13.2 Theravance Biopharma Overview
11.13.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.13.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Products and Services
11.13.5 Theravance Biopharma Recent Developments
11.14 Bausch Health
11.14.1 Bausch Health Corporation Information
11.14.2 Bausch Health Overview
11.14.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.14.4 Bausch Health Opioid Induced Constipation (OIC) Drug Products and Services
11.14.5 Bausch Health Recent Developments
11.15 Cosmo Pharmaceuticals SA
11.15.1 Cosmo Pharmaceuticals SA Corporation Information
11.15.2 Cosmo Pharmaceuticals SA Overview
11.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Products and Services
11.15.5 Cosmo Pharmaceuticals SA Recent Developments
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Corporation Information
11.16.2 Daewoong Pharmaceutical Overview
11.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Products and Services
11.16.5 Daewoong Pharmaceutical Recent Developments
11.17 C.B. Fleet Company
11.17.1 C.B. Fleet Company Corporation Information
11.17.2 C.B. Fleet Company Overview
11.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Products and Services
11.17.5 C.B. Fleet Company Recent Developments
11.18 Sucampo Pharmaceuticals
11.18.1 Sucampo Pharmaceuticals Corporation Information
11.18.2 Sucampo Pharmaceuticals Overview
11.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products and Services
11.18.5 Sucampo Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Opioid Induced Constipation (OIC) Drug Value Chain Analysis
12.2 Opioid Induced Constipation (OIC) Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid Induced Constipation (OIC) Drug Production Mode & Process
12.4 Opioid Induced Constipation (OIC) Drug Sales and Marketing
12.4.1 Opioid Induced Constipation (OIC) Drug Sales Channels
12.4.2 Opioid Induced Constipation (OIC) Drug Distributors
12.5 Opioid Induced Constipation (OIC) Drug Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
